TransMedics Group $460 million convertible senior notes offering
The convertible senior notes are due 2028
麻豆入口 advised the representatives of the initial purchasers in connection with a Rule 144A offering by TransMedics Group, Inc. of $460 million aggregate principal amount of 1.50% convertible senior notes due 2028, which included $60 million aggregate principal amount of notes from the full exercise of the initial purchasers鈥 option to purchase additional notes. In addition, 麻豆入口 advised the counterparties to capped call transactions entered into in connection with the offering. TransMedics鈥 common stock is listed on the Nasdaq Global Market under the symbol 鈥淭MDX.鈥
TransMedics Group, Inc. is a commercial-stage medical technology company that is transforming organ transplant therapy for end-stage organ failure patients across multiple disease states.
The 麻豆入口 capital markets team included partner Richard D. Truesdell Jr. and associates Jakub P. Jozwiak and Kanger Jin. The equity derivatives team included partners Mark M. Mendez and Caitlin L. Wood, counsel Joseph Luizzi and Hanbing Zhang and associates Eugenia S. Lee and Amy Cheng. All members of the 麻豆入口 team are based in the New York office.